Madrigal Pharmaceuticals (MDGL) Cash from Investing Activities (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of Cash from Investing Activities data on file, last reported at $192.2 million in Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at $192.2 million, up 17.28% year-over-year; the trailing twelve-month figure through Mar 2026 was $60.6 million (up 129.07% YoY), and the FY2025 annual result was $32.3 million, up 111.78% from the prior year.
• Cash from Investing Activities improved to $192.2 million in Q1 2026 per MDGL's latest filing, from $27.6 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $192.2 million in Q1 2026 and troughed at -$362.1 million in Q4 2023.
• A 5-year average of -$20.3 million and a median of $27.6 million in 2025 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2022 and 2024: Cash from Investing Activities soared 324.39% in 2022, then plunged 3171.65% in 2024.
• A 5-year view of Cash from Investing Activities shows it stood at $66.4 million in 2022, then plunged by 645.47% to -$362.1 million in 2023, then jumped by 86.76% to -$47.9 million in 2024, then surged by 157.52% to $27.6 million in 2025, then jumped by 596.85% to $192.2 million in 2026.
• Business Quant data shows MDGL's Cash from Investing Activities at $192.2 million in Q1 2026, $27.6 million in Q4 2025, and -$207.0 million in Q3 2025.